Recognition Supporting the Company’s Clinical Development Ambitions.
Odimma Therapeutics was selected as one of the five innovative biotechnology companies chosen to participate in the second edition of WiClub Health, a funding initiative supported by WiSEED, France’s leading equity crowdfunding platform, in partnership with SEMIA and Quest for Health.
The selection recognized the maturity of Odimma’s personalized cancer immunotherapy platform and its potential to address significant unmet medical needs in precision oncology.
At the time, the funding initiative was intended to support the company’s final regulatory milestones ahead of its first planned clinical study, reinforcing Odimma’s commitment to advancing innovative personalized immunotherapies toward patients.
This recognition reflects the growing confidence of the French innovation ecosystem in Odimma’s scientific platform and long-term clinical vision.
